Seeking Alpha

Amylin (AMLN) is looking to sell itself, according to sources, and has hired advisers to help...

Amylin (AMLN) is looking to sell itself, according to sources, and has hired advisers to help solicit possible offers. Several companies, possibly including Sanofi (SNY), are reportedly considering a bid to gain access to Amylin's diabetes portfolio.
Comments (1)
  • ralphey
    , contributor
    Comments (343) | Send Message
     
    Bydureon is a mega block buster not only is it capturing all the glp-1 market it is also pulling form the insulin market not ot mention the off label use of weight loss - and when it moves out to one mos injections - well it will be in huge demand ! . Icahn is absolutely wrong on a selling price of $22 - I'd look at more like $38
    23 Apr 2012, 09:57 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector